Adverum Biotechnologies Inc logo

ADVM - Adverum Biotechnologies Inc News Story

$10.81 0.3  3.0%

Last Trade - 25/09/20

Sector
Healthcare
Size
Mid Cap
Market Cap £806.9m
Enterprise Value £587.1m
Revenue £196k
Position in Universe 2322nd / 6417

BRIEF-Adverum Biotechnologies Doses First Patient In Cohort 4 Of OPTIC Phase 1 Clinical Trial Of ADVM-022

Mon 27th April, 2020 1:23pm
April 27 (Reuters) - Adverum Biotechnologies Inc  ADVM.O :
    * ADVERUM BIOTECHNOLOGIES DOSES FIRST PATIENT IN COHORT 4 OF
OPTIC
PHASE 1 CLINICAL TRIAL OF ADVM-022 INTRAVITREAL GENE THERAPY FOR
WET AMD

Source text for Eikon:  ID:nGNX7Wqmfz 
Further company coverage:  ADVM.O 

 ((Reuters.Briefs@thomsonreuters.com;))
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.